Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-03-16 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于召开2023年第二次临时股东大会通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 second extraordinary general meeting of shareholders for a company, including information on meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy forms. It does not contain financial statements or results but is focused on informing shareholders about the meeting logistics and agenda. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document is not an announcement of voting results, nor a report of financial performance or management discussion. Therefore, the correct classification is PSI.
2023-03-16 Chinese
独立董事关于第四届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting agenda item about purchasing director and officer liability insurance. It references compliance with company rules and laws, and the opinion is about the board meeting's decision process and proposal submission to the shareholders. The document is short (566 characters) and focuses on board/management matters rather than financial results or regulatory filings. It is not a full report, earnings release, or regulatory filing. Therefore, it fits best under Board/Management Information (MANG).
2023-03-16 Chinese
第四届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 21st meeting of the 4th Board of Directors of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to further disclosures on a public information website. The content focuses on board decisions such as amendments to disclosure management, purchase of directors and officers liability insurance, establishment of a subsidiary, and calling a shareholders meeting. There are no financial statements or detailed financial data presented. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or voting results declaration but rather a board meeting resolution announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (1617 characters), consistent with a meeting resolution announcement rather than a full report.
2023-03-16 Chinese
信息披露管理制度
Governance Information Classification · 95% confidence The document is titled "新乡拓新药业股份有限公司 信息披露管理制度" which translates to "Information Disclosure Management System of Xinxiang Tuoxin Pharmaceutical Co., Ltd." It is a detailed internal policy document outlining the company's procedures, responsibilities, and regulations for information disclosure. It references various regulatory laws and rules such as the Company Law, Securities Law, Shenzhen Stock Exchange rules, and China Securities Regulatory Commission requirements. The document covers definitions and procedures for periodic reports (annual and interim), temporary reports, information disclosure delays and exemptions, management responsibilities, and legal liabilities. It also includes internal forms and confidentiality commitments related to disclosure delays or exemptions. The content is about the governance and management of information disclosure rather than an actual financial report, earnings release, or announcement. It does not contain financial statements or results but rather the rules and processes for disclosure compliance. Therefore, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including disclosure policies and procedures.
2023-03-16 Chinese
关于对外投资设立子公司拓新药业（三亚）有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Xinxiang Tuoxin Pharmaceutical Co., Ltd. regarding the establishment of a wholly-owned subsidiary, Tuoxin Pharmaceutical (Sanya) Co., Ltd. It details the investment purpose, risks, and impact on the company. The document is a formal disclosure of a corporate action related to external investment and subsidiary formation. It is not a financial report, earnings release, or management discussion. It is also not a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it concerns company fundraising and capital structure changes through the establishment of a new subsidiary. The document length is short (1534 characters), but it contains substantive information about the investment, not just a report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2023-03-16 Chinese
关于购买董监高责任险的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's plan to purchase directors and officers liability insurance (董监高责任险). It includes details about the insurance plan, board and supervisory committee opinions, and the process for shareholder approval. There are no financial statements, earnings data, or detailed financial analysis. The document is a formal announcement of a corporate governance-related insurance purchase and the related board and supervisory approvals, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive content about the insurance plan and governance process. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about corporate governance and risk management measures that does not fit other specific categories.
2023-03-16 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.